Cereno's expanded access program for investigational therapy CS1 covers 10 PAH patients, following a Phase 2a clinical trial.

"It also plays an important role in the regulation of inflammation and tissue remodeling ... and fibrosis not only in the heart, but also in other organs and tissues such as the liver, lung ...

[3] As in this case, dyspnea on exertion is often the leading clinical symptom; however, dyspnea indicates that the characteristic vascular remodeling ... as interstitial lung fibrosis and ...

Some patients with diabetes develop a serious condition known as diabetic cardiomyopathy, which proceeds slowly and cannot be ...

Lixadesiran + pixofisiran is under clinical development by Sirnaomics and currently in Phase I for Solid Tumor.

Lixadesiran + pixofisiran is under clinical development by Sirnaomics and currently in Phase II for Hypertrophic Scars.

Tectonic's lead asset, TX45, is a long-acting Fc-relaxin fusion protein to treat group 2 pulmonary hypertension. Read why I'm ...

A Phase 2 trial of inhaled Longidaza in patients with idiopathic pulmonary fibrosis is planned for ... but also a key regulator of fibrotic tissue remodeling and chronic inflammation — key ...

The lung architecture is maintained in BOOP without fibrotic destruction. With CB, there may be severe and extensive fibrotic airway remodeling. CB obliterans and proliferative bronchiolitis with ...

Peptides, as versatile biological molecules, have garnered significant attention in scientific research due to their ...

Innate immune cells are white blood cells that mediate innate immunity and include basophils, dendritic cells, eosinophils, Langerhans cells, mast cells, monocytes and macrophages, neutrophils and ...